DRMADermata Therapeutics, Inc.

Nasdaq dermatarx.com


$ 2.08 $ -0.24 (-10.34 %)    

Tuesday, 17-Sep-2024 15:59:06 EDT
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.26 (-0.06 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.31 (-0.55 %)
$ 2.32
$ 2.02
$ 2.06 x 267
-- x --
$ 1.98 - $ 2.27
$ 1.29 - $ 17.55
24,231,941
na
3.05M
$ -17.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-21-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 09-27-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-dermata-therapeutics-raises-35m-through-private-placement-offering-19m-shares-and-warrants

The gross proceeds from the offering are expected to be approximately $3.5 million, prior to deducting placement agent's fe...

 maxim-group-maintains-buy-on-dermata-therapeutics-lowers-price-target-to-6

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target fro...

 dermata-therapeutics-q2-eps-418-misses-379-estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate o...

 dermata-therapeutics-entered-into-atm-agreement-with-hc-wainwright-providing-for-sale-by-co-of-12m-of-its-shares-of-common-stock-from-time-to-time

- Reuters 

 dermata-therapeutics-on-june-4-got-letter-from-nasdaq-that-company-has-regained-compliance-with-minimum-bid-price-requirement

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION